electroCore Reports Q3 2026 Revenue Growth and Narrowing Losses
electroCore (ECOR) reported third-quarter 2026 net sales of $9.7 million, a 12% increase year-over-year driven primarily by prescription sales growth within the U.S. Department of Veterans Affairs (VA). The company achieved an 88.5% gross margin and significantly improved its financial position, reducing its GAAP net loss to $1.3 million from $3.4 million in the prior-year period. Despite strong quarterly performance, management revised full-year 2026 revenue guidance due to delays in a commercial restructuring process. While Quell revenue grew 102% following the NeuroMetrix acquisition, the company faces headwinds including rising customer acquisition costs for its Truvaga brand and an FDA-related delay regarding the launch of an over-the-counter version of Quell.
Topics: EBITDA loss reduction gross margin guidance revision revenue growth VA prescription sales